Is Memorial Sloan Kettering Cancer Center Legit?

Memorial Sloan Kettering Cancer Center (MSKCC) demonstrates robust financial health, with its assets consistently growing over the past decade, reaching $8.54 billion in 2023. The organization has consistently reported significant revenues, with the latest available filing showing $1.67 billion in revenue against $1.51 billion in expenses for the period ending 202312, indicating a healthy operating surplus. This financial stability allows MSKCC to maintain its extensive operations in cancer research and treatment. While specific breakdowns of program, administrative, and fundraising expenses are not directly provided in the summary data, the overall financial scale suggests a substantial portion of spending is directed towards its mission. The consistent growth in assets and revenue, coupled with manageable liabilities, points to effective financial management. The absence of reported officer compensation in the provided data is notable and could indicate that executive compensation is reported differently or is not a significant direct expense from the summarized figures, which would be a positive indicator for transparency if further details are available in full filings. Overall, MSKCC appears to be a financially sound and well-managed organization. Its substantial assets and consistent revenue generation provide a strong foundation for its critical work in cancer care and research. Further detailed analysis of the full IRS 990 forms would be necessary to fully assess spending efficiency ratios and the specifics of executive compensation, but the available data suggests a strong financial position.